ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kawasuji, M.
Right arrow Articles by Watanabe, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawasuji, M.
Right arrow Articles by Watanabe, Y.

The Annals of Thoracic Surgery, Vol 55, 1205-1209, Copyright © 1993 by The Society of Thoracic Surgeons


ARTICLES

Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass

M Kawasuji, K Ueyama, N Sakakibara, T Tedoriya, Y Matsunaga, T Misaki and Y Watanabe
Department of Surgery (I), Kanazawa University School of Medicine, Japan.

To study the effect of low-dose aprotinin on hemostasis in patients undergoing cardiopulmonary bypass (CPB) for coronary artery bypass operations and to elucidate the mechanism of aprotinin action, we randomized 14 of 27 patients to receive 30,000 KIU/kg aprotinin in the CPB priming volume and 7,500 KIU/kg aprotinin intravenously each hour during CPB (1 patient was excluded from the aprotinin group because of protamine shock). Intraoperative and postoperative blood loss was significantly reduced in the aprotinin group. Antithrombin III level was significantly decreased, and the levels of thrombin-antithrombin III complexes were significantly increased during CPB in both groups, indicating activation of the clotting system. The marked increase in fibrin(ogen) degradation products during CPB in the control group, indicating enhanced fibrinolytic activity, was significantly reduced in the aprotinin group. alpha 2-Plasmin inhibitor was significantly reduced during CPB in the control group. The marked increase in alpha 2- plasmin inhibitor-plasmin complexes in the control group, indicating plasmin activity, was significantly reduced in the aprotinin group. A marked decrease in the platelet count was observed during CPB similarly in both groups. These findings demonstrated that low-dose aprotinin administration was effective in reducing intraoperative and postoperative blood loss and that activation of the clotting system during CPB was not followed by hyperfibrinolysis in aprotinin-treated patients. The improved hemostasis is mainly attributable to the prevention of hyperfibrinolysis during CPB.


This article has been cited by other articles:


Home page
CirculationHome page
J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor
Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery
Circulation, June 5, 2007; 115(22): 2801 - 2813.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
A. M. Mahdy and N. R. Webster
Perioperative systemic haemostatic agents
Br. J. Anaesth., December 1, 2004; 93(6): 842 - 858.
[Abstract] [Full Text] [PDF]


Home page
Asian Cardiovasc. Thorac. Ann.Home page
S. Rupinder, V. Manimozhi, G. Nagaraj, K. Vasanth, K. B. Sanjay, C. John, and K. Muralidhar
Aprotinin for Open Cardiac Surgery in Cyanotic Heart Disease
Asian Cardiovasc Thorac Ann, June 1, 2001; 9(2): 101 - 104.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. J. Munoz, N. J. O. Birkmeyer, J. D. Birkmeyer, G. T. O'Connor, and L. J. Dacey
Is {epsilon}-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery? : A Meta-Analysis
Circulation, January 12, 1999; 99(1): 81 - 89.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Misfeld, S. Dubbert, S. Eleftheriadis, H.-J. Siemens, T. Wagner, and H.-H. Sievers
Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations
Ann. Thorac. Surg., September 1, 1998; 66(3): 792 - 799.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
P. M. Mannucci
Hemostatic Drugs
N. Engl. J. Med., July 23, 1998; 339(4): 245 - 253.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
W. Dietrich, K. Schopf, M. Spannagl, M. Jochum, S. L. Braun, and H. Meisner
Influence of High- and Low-Dose Aprotinin on Activation of Hemostasis in Open Heart Operations
Ann. Thorac. Surg., January 1, 1998; 65(1): 70 - 77.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
N. Hayashida, T. Isomura, T. Sato, H. Maruyama, K. Kosuga, and S. Aoyagi
EFFECTS OF MINIMAL-DOSE APROTININ ON CORONARY ARTERY BYPASS GRAFTING
J. Thorac. Cardiovasc. Surg., August 1, 1997; 114(2): 261 - 269.
[Abstract] [Full Text]


Home page
J. Thorac. Cardiovasc. Surg.Home page
S. Cicek, U. Demirkilic, E. Ozal, E. Kuralay, H. Bingol, H. Tatar, and O. Y. Ozturk
POSTOPERATIVE USE OF APROTININ IN CARDIAC OPERATIONS: AN ALTERNATIVE TO ITS PROPHYLACTIC USE
J. Thorac. Cardiovasc. Surg., December 1, 1996; 112(6): 1462 - 1467.
[Abstract] [Full Text]


Home page
J. Thorac. Cardiovasc. Surg.Home page
R. G. H. Speekenbrink, C. R. H. Wildevuur, A. Sturk, and L. Eijsman
LOW-DOSE AND HIGH-DOSE APROTININ IMPROVE HEMOSTASIS IN CORONARY OPERATIONS
J. Thorac. Cardiovasc. Surg., August 1, 1996; 112(2): 523 - 530.
[Abstract] [Full Text]


Home page
Ann. Thorac. Surg.Home page
S. Cicek, U. Demirkilic, E. Kuralay, E. Ozal, and H. Tatar
Postoperative Aprotinin: Effect on Blood Loss and Transfusion Requirements in Cardiac Operations
Ann. Thorac. Surg., May 1, 1996; 61(5): 1372 - 1376.
[Abstract] [Full Text]


Home page
J. Thorac. Cardiovasc. Surg.Home page
G. E. Hill, A. Alonso, J. R. Spurzem, A. H. Stammers, and R. A. Robbins
APROTININ AND METHYLPREDNISOLONE EQUALLY BLUNT CARDIOPULMONARY BYPASS-INDUCED INFLAMMATION IN HUMANS
J. Thorac. Cardiovasc. Surg., December 1, 1995; 110(6): 1658 - 1662.
[Abstract] [Full Text]


Home page
CirculationHome page
J. H. Levy, R. Pifarre, H. V. Schaff, J. C. Horrow, R. Albus, B. Spiess, T. K. Rosengart, J. Murray, R. E. Clark, P. Smith, et al.
A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting
Circulation, October 15, 1995; 92(8): 2236 - 2244.
[Abstract] [Full Text]


Home page
J. Thorac. Cardiovasc. Surg.Home page
D. Green, J. Sanders, M. Eiken, C. A. Wong, J. Frederiksen, A. Joob, A. Palmer, A. Trowbridge, B. Woodruff, M. Moerch, et al.
RECOMBINANT APROTININ IN CORONARY ARTERY BYPASS GRAFT OPERATIONS
J. Thorac. Cardiovasc. Surg., October 1, 1995; 110(4): 963 - 970.
[Abstract] [Full Text]


Home page
Ann. Thorac. Surg.Home page
B. Liu, L. Tengborn, G. Larson, L. O. G. Radberg, A. Belboul, L. Dernevik, and D. Roberts
Half-Dose Aprotinin Preserves Hemostatic Function in Patients Undergoing Bypass Operations
Ann. Thorac. Surg., June 1, 1995; 59(6): 1534 - 1540.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1993 by The Society of Thoracic Surgeons.